JD.com (JD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
JD.com (JD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
JD.com (JD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
JD.com (JD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Listen to an album each morning, pick an easy instrument, don’t be afraid to write bad songs … you’ve got this! There are many benefits to making music, whether you are one or 100. But how should you approach choosing an instrument to play? And what are the best choices for a complete novice? We asked musicians for advice on how to live a more musical life, at any age. Continue reading...
Listen to an album each morning, pick an easy instrument, don’t be afraid to write bad songs … you’ve got this! There are many benefits to making music, whether you are one or 100. But how should you approach choosing an instrument to play? And what are the best choices for a complete novice? We asked musicians for advice on how to live a more musical life, at any age. Continue reading...
peterschreiber.media Novocure ( NVCR ) announced on Thursday that its cancer treatment device, Tumor Treating Fields (TTFields), reached the primary endpoint in its Phase 2 PANOVA-4 trial for patients with a certain form of pancreatic cancer. Based on topline data from PANOVA-4, the Swiss MedTech said that TTFields, as part of a combination regimen, improved disease control rate (DCR) with a stati...
peterschreiber.media Novocure ( NVCR ) announced on Thursday that its cancer treatment device, Tumor Treating Fields (TTFields), reached the primary endpoint in its Phase 2 PANOVA-4 trial for patients with a certain form of pancreatic cancer. Based on topline data from PANOVA-4, the Swiss MedTech said that TTFields, as part of a combination regimen, improved disease control rate (DCR) with a statistically significant effect compared to DCR reported in its Phase 3 MPACT study, which was used as a historical control. PANOVA-4 was designed to evaluate TTFields plus Roche’s ( RHHBY ) anti-PD-L1 antibody therapy, Tecentriq, and the chemotherapy regimen gem/nab-pac as a first-line therapy for metastatic pancreatic ductal adenocarcinoma. Detailed results indicate that patients on TTFields plus Tecentriq and gem/nab-pac showed 74.4% DCR in PANOVA-4 compared to 48% DCR in those who received only gem/nab-pac in MPACT. Regarding secondary endpoints, the objective response rate in patients in the TTFields arm was 34.6%, and their median overall survival was 9.7 months. The company added that TTFields treatment was well-tolerated, with device-related safety issues comparable to previous studies. Novocure ( NVCR ) stated that it will present additional data from the study at a future medical event. The company markets TTFields, which is approved in the U.S. for certain lung cancers, in partnership with the Chinese biotech Zai Lab ( ZLAB ) in several regions across Asia, including China. More on NovoCure NovoCure Limited 2025 Q4 - Results - Earnings Call Presentation NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching NovoCure outlines $675M–$705M 2026 revenue target as new indications fuel growth NovoCure Q4 2025 Earnings Preview
Kamada ( KMDA ), a biopharmaceutical company, announced that the FDA has approved its Kamada Plasma collection center in San Antonio, TX, following a February 2026 on-site inspection. The San Antonio center can support 50 donor beds and, at full capacity, produce up to 50K liters annually. It also plans to pursue EMA inspection and approval of its San Antonio facility following FDA clearance. The ...
Kamada ( KMDA ), a biopharmaceutical company, announced that the FDA has approved its Kamada Plasma collection center in San Antonio, TX, following a February 2026 on-site inspection. The San Antonio center can support 50 donor beds and, at full capacity, produce up to 50K liters annually. It also plans to pursue EMA inspection and approval of its San Antonio facility following FDA clearance. The center could make $8–$10M in annual revenues from normal source plasma at full capacity. More on Kamada Kamada's Pipeline And Biosimilars Set Stage For Future Earnings Expansion Kamada Ltd. (KMDA) Q4 2025 Earnings Call Transcript Kamada 2025/2026 Outlook: Evaluating Revenue Growth And Product Drivers Kamada forecasts double-digit profitable growth in 2026 Seeking Alpha’s Quant Rating on Kamada
Gap stock rebounds after earnings drop, helped by AI news, though shares remain volatile as Wall Street continues to assess the company’s turnaround progress.
Gap stock rebounds after earnings drop, helped by AI news, though shares remain volatile as Wall Street continues to assess the company’s turnaround progress.
halbergman/iStock via Getty Images Boyd Gaming ( BYD ) opened its first new casino in the Las Vegas area in more than 20 years when the Cadence Crossing property opened in Henderson on March 25. The project is a smaller, locals-oriented casino near the Cadence master-planned community on Boulder Highway. The casino operator has positioned it as part of its long-term growth strategy in Southern Nev...
halbergman/iStock via Getty Images Boyd Gaming ( BYD ) opened its first new casino in the Las Vegas area in more than 20 years when the Cadence Crossing property opened in Henderson on March 25. The project is a smaller, locals-oriented casino near the Cadence master-planned community on Boulder Highway. The casino operator has positioned it as part of its long-term growth strategy in Southern Nevada. Before Cadence Crossing, the last casino Boyd ( BYD ) operated in Las Vegas was Joker’s Wild, the longtime Henderson property that Cadence Crossing replaces. Joker's Wild had been one of Boyd’s familiar local casinos in the valley for years, serving the local market rather than tourists. Its replacement with a new, modern property reflects Boyd's ( BYD ) strategy of refreshing its local-market presence instead of building a large new resort. "With strong residential growth continuing throughout the neighborhood, we believe Cadence Crossing Casino will be well positioned to deliver a strong return on our investment. And with significant land still available at Cadence Crossing for future development, we will have the opportunity to expand this property to meet the growing demand," stated CEO Keith Smith on the company's earnings conference call. Boyd Gaming ( BYD ) operates 10 casino properties in the Las Vegas region, including Aliante, The Orleans, Gold Coast, Suncoast, Sam’s Town, Cannery, California, Fremont, Main Street Station, and Cadence Crossing. Shares of Boyd Gaming ( BYD ) are relatively flat for 2026 but stand more than 20% higher than where they stood a year ago. More on Boyd Gaming Boyd Gaming: 2026 Is The Investment Year Boyd Gaming Corporation (BYD) Q4 2025 Earnings Call Transcript Boyd Gaming: 6 Straight Double Beats And Still Room To Run (Earnings Preview) Casino swap: Boyd Gaming sells Shreveport property to Bally's Boyd Gaming outlines $650M–$700M capital plan for 2026 amid continued core customer growth and major property investments
Steel manufacturer Nucor is a safe bet amid the Iran war, and its recent sell-off could offer a buying opportunity for investors, according to UBS. The investment firm upgraded shares to buy from neutral. It also raised its price target on shares to $190 from $184, suggesting 15% upside from Wednesday's close. "The sell off presents [a] buying opportunity in [a] relatively insulated market," analy...
Steel manufacturer Nucor is a safe bet amid the Iran war, and its recent sell-off could offer a buying opportunity for investors, according to UBS. The investment firm upgraded shares to buy from neutral. It also raised its price target on shares to $190 from $184, suggesting 15% upside from Wednesday's close. "The sell off presents [a] buying opportunity in [a] relatively insulated market," analyst Andrew Jones said in a note to clients. "We think US steel producers are largely insulated from the Iran conflict." NUE YTD mountain NUE year to date The war has sparked supply chain bottlenecks affecting chemicals, steel and aluminum, among other manufactured imports and exports. Amid those disruptions, steel stocks, including Nucor, have taken a hit. The VanEck Steel ETF (SLX) plunging nearly 11% since the start of the conflict. Nucor has shed 6% over the past month. However, a combination of tailwinds, including federal contracts for steel manufacturers and a decline in U.S. steel imports, could also propel the company's shares higher, according to UBS. "We like the setup for NUE given little direct hit from energy [and] project growth (bar mills, towers & coating, Brandenburg, W Virginia) in a federally supported higher price/volume environment," Jones wrote. Earlier this month, a subsidiary of AMI Metals announced it had clinched a roughly $2.2 billion government contract to "build the wall" along the U.S.-Mexico border — a development that is bullish for other metals producers, including Nucor. Meanwhile, President Donald Trump hiked tariffs on steel to 50% from 25% last June, making it more costly to source the building material from overseas. UBS' call is in line with consensus on Wall Street. Of the 18 analysts covering Nucor, two-thirds have a buy or strong buy on shares.
Yeahka press release ( YHEKF ): FY T otal revenue reached RMB3,310.5 million, representing a year-on-year increase of 7.3%. Profit reached RMB92.2 million, representing an increase of 11.9% compared to 2024. More on Yeahka Historical earnings data for Yeahka Financial information for Yeahka
Yeahka press release ( YHEKF ): FY T otal revenue reached RMB3,310.5 million, representing a year-on-year increase of 7.3%. Profit reached RMB92.2 million, representing an increase of 11.9% compared to 2024. More on Yeahka Historical earnings data for Yeahka Financial information for Yeahka
Response from British fashion industry has been jubilant and Kane’s first Mulberry collection is reportedly to be unveiled at London fashion week 2027 British fashion designer Christopher Kane has been named as the new creative director of Mulberry. The Glaswegian-born designer will relaunch the heritage English brand’s ready-to-wear womenswear collection, with his debut reportedly to be unveiled ...
Response from British fashion industry has been jubilant and Kane’s first Mulberry collection is reportedly to be unveiled at London fashion week 2027 British fashion designer Christopher Kane has been named as the new creative director of Mulberry. The Glaswegian-born designer will relaunch the heritage English brand’s ready-to-wear womenswear collection, with his debut reportedly to be unveiled next September at London fashion week, before landing in stores and online from January 2027. Continue reading...
Nvidia (NVDA) board member Mark A. Stevens sold $38.5 million in shares of the AI chipmaker, according to a recent SEC (Securities and Exchange Commission) filing. Stevens offloaded 221,682 shares in multiple transactions, signaling a significant monetization of his holdings. Prior to this, he sold over $100 million worth of shares in December. While Stevens’ sale may raise eyebrows, analysts rema...
Nvidia (NVDA) board member Mark A. Stevens sold $38.5 million in shares of the AI chipmaker, according to a recent SEC (Securities and Exchange Commission) filing. Stevens offloaded 221,682 shares in multiple transactions, signaling a significant monetization of his holdings. Prior to this, he sold over $100 million worth of shares in December. While Stevens’ sale may raise eyebrows, analysts remain confident in Nvidia’s growth, still projecting a potential 56% upside for the stock at an average